Effect of lopinavir/ritonavir on the pharmacokinetics of selexipag an oral prostacyclin receptor agonist and its active metabolite in healthy subjects

Multiple-Dose Up-Titration Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Selexipag, an Orally Available Selective Prostacyclin Receptor Agonist, in Healthy Subjects

(2014) Shirin Bruderer et al.   PHARMACOLOGY

Selexipag: an oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension

(2012) Gérald Simonneau et al.   EUROPEAN RESPIRATORY JOURNAL

How has epoprostenol changed the outcome for patients with pulmonary arterial hypertension?

(2010) R. Barst   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

Selexipag: A Selective Prostacyclin Receptor Agonist that Does Not Affect Rat Gastric Function

(2010) K. Morrison et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

A review of prostaglandin analogs in the management of patients with pulmonary arterial hypertension

(2009) Kamal K. Mubarak   RESPIRATORY MEDICINE

Induction Effects of Ritonavir: Implications for Drug Interactions

(2008) Michelle M Foisy et al.   ANNALS OF PHARMACOTHERAPY

Effect of an Antiretroviral Regimen Containing Ritonavir Boosted Lopinavir on Intestinal and Hepatic CYP3A, CYP2D6 and P-glycoprotein in HIV-infected Patients

(2008) C Wyen et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Prostacyclin therapies for the treatment of pulmonary arterial hypertension

(2008) M. Gomberg-Maitland et al.   EUROPEAN RESPIRATORY JOURNAL

Prevalence of HIV-related Pulmonary Arterial Hypertension in the Current Antiretroviral Therapy Era

(2007) Olivier Sitbon et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE